Inclusion Criteria:

          1. Diagnosed as stage Ⅳ naive EGFR wild-type lung adenocarcinoma by image, tissue and/or
             cytology; or relapse after operation (if the patient received adjuvant chemotherapy
             and the interval between the last chemotherapy and relapse is at least six months. The
             detection method of EGFR mutation is ARMS.

          2. EML4-ALK fuse gene is negative and the detection of EML4-ALK is FISH or ventana IHC.

          3. There should be at least one measurable lesions (by CT or MRI)

          4. No other cancer history ( except skin squamous cell carcinoma after surgery)

          5. Age between 18 and 75 years old

          6. World health organization- Eastern Cooperative Oncology Group Performance Status 0-1

          7. Life expectancy more than 3 months and can be followed-up

          8. Patients must have adequate organ and marrow functions as defined below: white blood
             cells: more than 3.5×109/L, Neutrophils: more than 1.5×109/L, Platelets: more than
             80×109/L, Hemoglobin more than 90g/L, Serum total bilirubin less than 1.5 folds of the
             upper normal limit (ULN), Serum glutamic-oxal

             (o) acetic transaminase: less than 2.5×ULN (if there is liver metastasis less than
             5×ULN); Serum creatinine: less than 1.0×ULN, Prothrombin time, Active partial
             thromboplastin time, Fibrinogen, Thrombin time are in normal ranges.

          9. Women of child-bearing period must take effective contraceptive measures during all
             the time of study. During the period of study the results of blood and urine pregnancy
             test should be negative.

         10. Men should take effective contraceptive measures from the beginning of therapy to one
             month after the last cycle of chemotherapy.

         11. Willing to comply with the ban and constraints for this study protocol specified.

         12. Informed consent and willing to participate in this study.

        Exclusion Criteria:

          1. Accepted other study drugs 30 days before the beginning of this study.

          2. Brain metastases with clinical symptoms ( with exception of being controlled after
             radiation)

          3. Active viral or bacterial infection and can't be controlled with appropriate
             anti-infection treatment

          4. Known as HIV infection, syphilis serology reaction positive, active hepatitis B virus
             or hepatitis C virus infection

          5. Suffering from mental illness or other illness, such as heart or lung disease,
             diabetes, etc. that can not be controlled, and can not be coped with study treatment
             and monitoring requirements.

          6. Known allergy to any kind of component of study drugs

          7. Active rheumatic diseases

          8. Organ transplant recipients

          9. Poor compliance

         10. Pregnant women

         11. Lactating women